Competing pursuits
The authors declare the next potential conflicts of curiosity: EKM: consulting or advisory position, honoraria, analysis funding, and journey lodging/bills from Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline, and Takeda. TH and UB: no competing pursuits. HJS: advisory position or honoraria from AbbVie, Amgen, Bristol Myers Squibb/Celgene, Chugai, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Roche, Sanofi, Sebia, TAD, and Takeda; journey lodging/bills from Amgen, Bristol Myers Squibb/ Celgene, GlaxoSmithKline, Janssen-Cilag, and Sanofi. SZ: consulting or advisory position for Janssen-Cilag, Bristol Myers Squibb, Sanofi, Oncopeptides, and Takeda (all funds to the establishment); analysis funding from Janssen-Cilag and Takeda. MSR: consulting or advisory position for AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Novartis, Roche, and Sanofi; honoraria from AbbVie and GlaxoSmithKline; analysis funding from Novartis and Sanofi. MM: consulting or advisory position for AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and Takeda; honoraria from Amgen, Bristol Myers Squibb, Janssen, and Takeda; analysis funding from Incyte; journey lodging/bills from Amgen. LP honoraria from Sanofi, GlaxoSmithKline, and Pfizer. KM: honoraria from Amgen, Bristol-MyersSquibb/Celgene, Janssen, Takeda, Sanofi, GlaxoSmithKline, and Pfizer. PB: no competing pursuits. MB: consulting or advisory position for Janssen, Celgene/Bristol Myers Squibb, Amgen, Sanofi, Takeda, and Menarini; speaker’s bureau for Amgen, Takeda, Sanofi, and Celgene/Bristol Myers Squibb. IWB: no competing pursuits. JD: consulting or advisory position for Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Sanofi, Takeda, Celgene, and Roche; journey lodging/bills from Roche, Celgene, and Bristol Myers Squibb. BB: honoraria from Janssen, GlaxoSmithKline, Amgen, and Sanofi. RF: honoraria from Bristol Myers Squibb/Celgene, Janssen, Sanofi, and GlaxoSmithKline; consulting or advisory position for Bristol Myers Squibb/Celgene, Janssen, and GlaxoSmithKline; journey lodging/bills from Bristol Myers Squibb/Celgene, Janssen, and GlaxoSmithKline. PR and BvdH: no competing pursuits. MH: consulting or advisory position for Amgen, Bayer Very important, Bristol Myers Squibb/Celgene, Gilead, GlaxoSmithKline, Jazz Prescribed drugs, Novartis, Roche, and Takeda; invitation as speaker for Novartis. IvM: consulting or advisory position for Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Sanofi, and Takeda; honoraria from Sanofi; journey lodging/bills from Takeda. UG: inventory and different possession pursuits for Biontech; honoraria from Boehringer Ingelheim, Amgen, Astra Zeneca, Bristol Myers Squibb/Celgene, MSD Oncology, Sanofi Aventis, Fujifilm, Novartis, and Celltrion; consulting or advisory position for Amgen, MSD oncology; analysis funding from Ipsen (to the establishment), Macrogenics (to the establishment); journey lodging/bills from Boehringer Ingelheim and GlaxoSmithKline. CM-T: research funding from Pfizer and BioliveRx. MB: honoraria from AbbVie, Amgen, Bristol-Myers Squibb/Celgene, Janssen, Novartis, and Sanofi. CS: honoraria from AbbVie, Amgen, Bristol Myers Squibb, Glaxo Smith Kline, Janssen, Pfizer, Oncopeptides, Sanofi, and Takeda; journey lodging/bills from Bristol Myers Squibb, Janssen, Novartis, and Takeda; analysis funding from Janssen, Novartis, and Takeda. MAD: honoraria from Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, BeiGene, and Sanofi; consulting or advisory position for Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, BeiGene, and Sanofi. JH: consulting or advisory position for Adaptive, Amgen, Axxes Community, Bristol Myers Squibb/Celgene, Glaxo Smith Kline, Janssen, Oncopeptides, Oncotracker, Sanofi, and Skyline; invited talks for Amgen, Beigene, Beijing Medical Award Basis, Curio Science, and Janssen. KCW: honoraria from Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, Bristol Myers Squibb/Celgene, BeiGene, Janssen, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline, and Takeda; consulting or advisory position for Abbvie, Amgen, Adaptive Biotech, Bristol Myers Squibb/Celgene, BeiGene, Janssen, GlaxoSmithKline, Karyopharm, Oncopeptides, Pfizer, Roche Pharma, Sanofi, and Takeda; analysis funding from Amgen (to the establishment), Bristol Myers Squibb/Celgene (to the establishment), Janssen (to the establishment), and Sanofi (to the establishment). MC: consulting or advisory position for AbbVie, Amgen, Bristol Myers Squibb, GSK, Janssen, Pfizer, and Sanofi; speaker’s bureau for Bristol Myers Squibb and Janssen. PS: consulting or advisory position for Celgene/Bristol Myers Squibb, Janssen, Karyopharm, and Sanofi; analysis funding from Celgene/Bristol Myers Squibb, Janssen, Karyopharm, and Sanofi. HG: consulting for Adaptive Biotechnology, Amgen, Bristol Myers Squibb, and Janssen; honoraria from Amgen, Bristol Myers Squibb, Celgene, Chugai, GlaxoSmithKline, Janssen, and Novartis; analysis funding from Amgen, Bristol Myers Squibb, Celgene, Chugai, Incyte, Janssen, Molecular Associate, MSD, Mundipharma, and Novartis; grants from Amgen, Celgene, Chugai, Janssen, and Johns Hopkins College.
